Iraq Pharmaceuticals & Healthcare Report Q1 2015
Headline Expenditure Projections
- Pharmaceuticals: IQD1,620bn (USD1.39bn) in 2013 to IQD1,734bn (USD1.49bn) in 2014; +7.0% in local currency and +7.2% in US dollar terms. Forecast slightly higher than in Q414.
- Healthcare: IQD9,701bn (USD8.33bn) in 2013 to IQD10,331bn (USD8.88bn) in 2014; +6.5% in local currency and +6.7% in US dollar terms. Forecast lower than Q414 due to macroeconomic conditions.
Iraq's Pharmaceutical Risk/Reward Index (RRI) score for Q115 reflects the market's potential and its strong economic growth prospects. It performs better in terms of Rewards than Risks. In Q115 Iraq scores 40.5 out of 100, making it the 17th most attractive pharmaceutical market in the Middle East and African region. Its score has slightly decreased and the country lost one position in our index from Q414.
Key Trends And Developments
- In November 2014, Baghdad Governorate opened a health centre for citizens in the Nahrwan area of northern Baghdad, according to IraqiNews.com. The governorate stated that the three-floor building was ready within 300 days to provide health services for citizens in the area. The Baghdad Health...
The Iraq Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Iraq Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Iraq pharmaceutical and healthcare industry.
- Benchmark BMI's pharmaceutical and healthcare market forecasts for Iraq, to test other views - a key input for successful budgeting and strategic business planning in the Iraqi pharmaceutical and healthcare market.
- Target business opportunities and risks in the Iraqi pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Iraq.
- Assess the activities, strategy and market position of your competitors via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
BMI Industry View
An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMIs forecast analysis, and taken together with BMIs political, economic and business environment SWOTs, it gives a complete overview of market climate.
BMI Industry Forecast Scenario
Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:
Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per 000 population).
Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
OTC Drug Market: OTC sales (USDbn & % of total sales).
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.
BMIs Pharmaceuticals and Healthcare Risk Reward Index
BMIs Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the markets risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.
A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape
A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.
The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMIs industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.
The competitiveness of Iraq's pharmaceutical sector, as well as the ability of the government to ramp up healthcare investment , is linked to oil prices and additional foreign investment, which is, in turn, highly dependent on the security situation. The long-term prospects for the Iraqi pharmaceutical and healthcare markets therefore remain promising given rising healthcare expenditure and population growth. The Iraqi government reportedly pledged to invest USD12bn into healthcare expansion in 2014 , and the Ministry of Health recently awarded 18 health project contracts worth USD276mn. In the short term however, numerous factors will continue to hamper market growth , such as expected further political unrest with accompanying high levels of violence and even the possibility of a partition of the country.
BMI Industry View
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Iraq 2010-2018)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Iraq 2010-2018)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Iraq 2010-2018)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Iraq 2010-2018)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Iraq 2012-2018)
Table: Pharmaceutical Trade Data And Forecasts local currency (Iraq 2012-2018)
Other Healthcare Data
Key Risks To BMI's Forecast Scenario
Iraq: Growth Forecasts Revised Downward
Table: Economic Activity (Iraq 2009-2018)
Industry Risk Reward Ratings
Middle East & Africa Risk/Reward Index
Iraq Risk/Reward Ratings
Industry Trends And Developments
Healthcare System Reform
Intellectual Property Issues
Pharmaceutical Company Developments
Pharmaceutical Retail Sector
Table: Iraq's Population By Age Group, 1990-2020 ('000)
Table: Iraq's Population By Age Group, 1990-2020 (% of total)
Table: Iraq's Key Population Ratios, 1990-2020
Table: Iraq's Rural And Urban Population, 1990-2020
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Ratings Methodology
Table: Pharmaceutical Risk/Reward Ratings Indicators
This report does not have a list of Companies Mentioned available
This report does not have a press release associated with it